The patent imagines self-driving cars that will repossess themselves.
Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.
The non-profit Freedom to Operate used research from chemists and crystallographers to argue in a legal filing that Compass’ form of synthetic psilocybin is not a new invention.
A recent application from CB Therapeutics on biosynthetic psilocybin is emblematic of the IP concerns around novelty and obviousness the psychedelic field will face.
In a series of open letters and statements, investors have been debating how patents will shape the future—who will get to use psychedelics, and who will profit.
Psychedelics now appear in patent applications for Philip Morris e-cigarettes, periodontal disease, hair loss, weight loss, and food allergies.
Compass Pathways, a Peter Thiel-backed psychedelic mental health company, has made patent application claims on aspects of psilocybin-assisted therapy as basic as using soft furniture and holding hands.
Court documents reveal how the two spin bike companies went from potential partners to hated rivals.
Amazon’s latest patent aims to combine data from various sources to identify cryptocurrency users for subscribers including the taxman and cops.
The company aims to patent virtual reality technology that lets you jack in while on the road.